Metformin overdose in the ICU – signs and dapagliflozin effects
Part of Hormones & metabolism, Mental health clinical trials.
This study looks at patients who are in the ICU after taking too much metformin (a diabetes drug), sometimes along with another drug called dapagliflozin (Farxiga). The goal is to understand how overdose affects the body and what signs doctors should watch for.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were admitted to an intensive care unit (ICU) because of a drug overdose
- You took metformin (a diabetes medicine) before or during the overdose
- You may have also taken another diabetes medicine called dapagliflozin (Farxiga), but not by itself — only together with metformin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
This study looks at patients in intensive care who had lactic acidosis, to see if taking metformin before admission played a role. It may help understand how metformin affects recovery.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests a new medication called LID104 added to your usual metformin to see if it improves blood sugar control in people with type 2 diabetes. If you qualify, you'll get the study drug or a placebo (inactive pill) to compare how well it works.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
Hear when a new Drug Overdose trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.